- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Psychedelic merger to create AtaiBeckley completes | ||
| Mi | Dismay as FDA declines to approve Biohaven's ataxia drug | ||
| Mi | UK facing alarming loss of scientific talent overseas | ||
| Mi | Novo Nordisk cuts guidance again on weaker GLP-1 growth | ||
| Di | Bidding war breaks out as Novo raises Metsera bid to $10bn | ||
| Di | Sarepta shares slide as DMD treatment woes pile up | ||
| Di | UCB bags FDA okay for first drug to treat rare disease TK2d | ||
| Di | Lilly reveals $3bn orforglipron facility in Netherlands | ||
| Mo | uniQure poleaxed as FDA blocks Huntington's therapy | ||
| Mo | Pfizer files another lawsuit against Metsera, Novo Nordisk | ||
| Mo | Tylenol maker Kenvue agrees $48.7bn Kimberly-Clark takeover | ||
| Mo | Roche's Gazyva breaks new ground in lupus | ||
| Mo | CDER head Tidmarsh 'on leave' and is sued by drugmaker | ||
| Mo | Free Wegovy trialled in deprived areas of Scotland | ||
| Fr | Medical group advises against leucovorin for autism | ||
| Fr | "Significant shift" as NICE widens prostate cancer drug use | ||
| Fr | AZ trumpets results for new injectable C5 drug for gMG | ||
| Fr | MSD still seeking deals 'with urgency' after Verona takeover | ||
| Fr | Electra banks $183m for sHLH drug, and other biofinancings | ||
| 30.10. | Lilly climbs on stellar GLP-1 drug sales gain | ||
| 30.10. | Thermo bids $8.9bn for clinical trial data firm Clario | ||
| 30.10. | FDA plan will cut testing requirements for biosimilars | ||
| 30.10. | Novo tries to push Pfizer aside with $9bn bid for Metsera | ||
| 30.10. | As UK mulls prostate cancer screening, study shows benefit | ||
| 29.10. | MSD, Eisai abandon combination trial in liver cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .